Pfizer CEO Albert Bourla said the company plans to expand human trials of its experimental coronavirus vaccine to thousands of test patients by September, reported CNBC.
The drugmaker, which is partnered with BioNTech on the work, dosed its vaccine candidate BNT162 into the first human participants in the US last week, and hopes to test up to 360 people in the trial.
Bourla said they are currently testing four different vaccine variations, adding "we are collecting data as we speak in real time so we know, we are monitoring the safety of the doses."
Pfizer will have conclusive data on which vaccine variation stands out in June or July, he added.
The CEO indicated that if one or two variations show signs of success, the company will ramp up trials, and then in September launch a broad large-scale study with thousands of participants if a vaccine proves to be successful.
To read more NewsPoints articles, click here.